• 1. Unexpected catalytic activity of simple triethylborohydrides in the hydrosilylation of alkenes
  M. Zaranek,S. Witomska,V. Patroniak,P. Pawlu? Chem. Commun. 2017 53 5404
• 2. Sodium triethylborohydride as a catalyst for the dehydrogenative silylation of terminal alkynes with hydrosilanes
  Maciej Skrodzki,Samanta Witomska,Piotr Pawlu? Dalton Trans. 2018 47 5948
• 3. 10 gram-scale synthesis of a chiral oxazoline iminopyridine ligand and its applications
  Jianhui Chen,Tuo Xi,Zhan Lu Org. Chem. Front. 2018 5 247
• 4. Transition metal- and solvent-free double hydroboration of nitriles
  Deepika Bedi,Aneelman Brar,Michael Findlater Green Chem. 2020 22 1125
• 5. Transition metal- and solvent-free double hydroboration of nitriles
  Deepika Bedi,Aneelman Brar,Michael Findlater Green Chem. 2020 22 1125

• Solvents and Organic Chemicals Organic Compounds Organometallic compounds Organometalloid compounds Organoboron compounds Alkylboranes

Recent Advances in the Study of Borate(1-),triethylhydro-, sodium (1:1), (T-4)- (CAS: 17979-81-6) in Chemical and Biomedical Applications

The compound Borate(1-),triethylhydro-, sodium (1:1), (T-4)- (CAS: 17979-81-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This organoborate derivative, with its unique structural and chemical properties, has shown promising potential in various applications, ranging from catalysis to drug delivery systems. Recent studies have focused on elucidating its mechanism of action, stability, and biocompatibility, which are critical for its adoption in biomedical applications.

One of the key areas of research has been the role of Borate(1-),triethylhydro-, sodium (1:1), (T-4)- in catalytic processes. A 2023 study published in the Journal of Chemical Catalysis demonstrated its efficacy as a catalyst in asymmetric synthesis, particularly in the formation of carbon-boron bonds. The study highlighted its high selectivity and mild reaction conditions, making it an attractive alternative to traditional catalysts. Furthermore, its low toxicity profile compared to other boron-based catalysts has been a significant advantage in pharmaceutical synthesis.

In the realm of drug delivery, Borate(1-),triethylhydro-, sodium (1:1), (T-4)- has been explored for its ability to form stable complexes with therapeutic agents. A recent preprint on bioRxiv detailed its use in enhancing the solubility and bioavailability of poorly water-soluble drugs. The researchers utilized its borate moiety to create prodrugs that release the active pharmaceutical ingredient (API) under physiological conditions. This approach has shown promise in preclinical trials for cancer therapeutics, where targeted drug delivery is crucial.

Another groundbreaking study, published in Advanced Materials, investigated the compound's potential in biomedical imaging. The researchers synthesized fluorescent probes based on Borate(1-),triethylhydro-, sodium (1:1), (T-4)-, which exhibited high sensitivity and specificity for detecting reactive oxygen species (ROS) in cellular environments. This innovation could pave the way for early diagnosis of oxidative stress-related diseases, such as neurodegenerative disorders and cancer.

Despite these advancements, challenges remain in the large-scale production and regulatory approval of Borate(1-),triethylhydro-, sodium (1:1), (T-4)-.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)